SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Cohen S, Ushiro H, Stoscheck C, Chinkers M. A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J Biol Chem. 1982; 257: 15231531.
  • 2
    Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19: 183232.
  • 3
    McCune BK, Earp HS. The epidermal growth factor receptor tyrosine kinase in liver epithelial cells. The effect of ligand-dependent changes in cellular location. J Biol Chem. 1989; 264: 1550115507.
  • 4
    Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer. 2001; 92: 13311346.
  • 5
    Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001; 37( Suppl 4): S9S15.
  • 6
    Ciardiello F, Bianco R, Damiano V, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res. 1999; 5: 909916.
  • 7
    Ciardiello F, Tortora G. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer. 2003; 39: 13481354.
  • 8
    Baselga J. The EGFR as a target for anticancer therapy—focus on cetuximab. Eur J Cancer. 2001; 37( Suppl 4): S16S22.
  • 9
    Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barcelona). 2005; 41: 107127.
  • 10
    Starling N, Cunningham D. Second-line therapy for advanced colorectal carcinoma. Curr Oncol Rep. 2005; 7: 173180.
  • 11
    Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005; 23: 18031810.
  • 12
    Hoos A, Urist MJ, Stojadinovic A, et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol. 2001; 158: 12451251.
  • 13
    Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Storkel S. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem. 2004; 52: 893901.
  • 14
    Erlichman C, Sargent DJ. New treatment options for colorectal cancer. N Engl J Med. 2004; 351: 391392.
  • 15
    Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351: 337345.
  • 16
    Saltz LB, Meropol NJ, Loehrer PJ Sr., Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004; 22: 12011208.
  • 17
    Hilbe W, Gachter A, Duba HC, et al. Comparison of automated cellular imaging system and manual microscopy for immunohistochemically stained cryostat sections of lung cancer specimens applying p53, ki-67 and p120. Oncol Rep. 2003; 10: 1520.
  • 18
    Luftner D, Henschke P, Kafka A, et al. Discordant results obtained for different methods of HER-2/neu testing in breast cancer—a question of standardization, automation and timing. Int J Biol Markers. 2004; 19: 113.